Korea University Ansan Hospital Researchers Have Published New Study Findings on Atopic Dermatitis (Drug survival analysis of dupilumab and associated predictors in patients with atopic dermatitis in South Korea: single-center, retrospective...).

Předmět:	CONNECTIVE tissue diseases ATOPIC dermatitis SKIN diseases DRUG therapy REPORTERS & reporting
Zdroj:	Immunotherapy Weekly; 8/13/2024, p1292-1292, 1p
Abstrakt:	A recent study conducted at Korea University Ansan Hospital examined the drug survival rate of dupilumab, a biologic medication used to treat moderate-to-severe atopic dermatitis (AD), in South Korean patients. The study found that the overall 4-year dupilumab survival rate was 87.9%. Patients with lower eczema area and severity index (EASI) scores at baseline and those without insurance coverage for dupilumab were more likely to discontinue the treatment. This study provides valuable long-term data on dupilumab drug survival in Asia and identifies predictors of discontinuation. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu